Īrija - angļu - HPRA (Health Products Regulatory Authority)

glaxosmithkline (ireland) limited - epoprostenol - powder and solvent for solution for infusion - 0.5 milligram(s) - platelet aggregation inhibitors excl. heparin; epoprostenol

Singapūra - angļu - HSA (Health Sciences Authority)

johnson & johnson international (singapore) pte ltd - epoprostenol sodium 0.531mg eqv epoprostenol - injection, powder, for solution - epoprostenol sodium 0.531mg eqv epoprostenol 0.5mg

Singapūra - angļu - HSA (Health Sciences Authority)

johnson & johnson international (singapore) pte ltd - epoprostenol sodium 1.593mg eqv epoprostenol - injection, powder, for solution - epoprostenol sodium 1.593mg eqv epoprostenol 1.5mg

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - heparin sodium, quantity: 5000 iu/ml - injection, solution - excipient ingredients: water for injections; hydrochloric acid; sodium hydroxide - indications as at 26 november 2001: prophylaxis and treatment of thromboembolic disorders such as thrombophlebitis, pulmonary embolism, coronary or venous thrombosis and occlusive vascular disease. as a low-dose regimen for the prevention of thromboembolic complications arising as a result of cardiac and arterial surgery. as an anticoagulant during blood transfusions, extracorporeal circulation, dialysis and other perfusion techniques and in blood samples for laboratory purposes.

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - heparin sodium, quantity: 1000 iu/ml - injection, solution - excipient ingredients: water for injections; hydrochloric acid; sodium hydroxide - indications as at 26 november 2001: prophylaxis and treatment of thromboembolic disorders such as thrombophlebitis, pulmonary embolism, coronary or venous thrombosis and occlusive vascular disease. as a low-dose regimen for the prevention of thromboembolic complications arising as a result of cardiac and arterial surgery. as an anticoagulant during blood transfusions, extracorporeal circulation, dialysis and other perfusion techniques and in blood samples for laboratory purposes.

Jaunzēlande - angļu - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - heparin sodium 1000 iu/ml; heparin sodium 1000 iu/ml - solution for injection - 1000 iu/ml - active: heparin sodium 1000 iu/ml excipient: hydrochloric acid sodium hydroxide water for injection active: heparin sodium 1000 iu/ml excipient: benzyl alcohol hydrochloric acid sodium hydroxide water for injection

Jaunzēlande - angļu - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - heparin sodium 25000 iu/ml - solution for injection - 25000 iu/ml - active: heparin sodium 25000 iu/ml excipient: hydrochloric acid sodium hydroxide water for injection

Jaunzēlande - angļu - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - heparin sodium 5000 iu/ml; heparin sodium 5000 iu/ml - solution for injection - 5000 iu/ml - active: heparin sodium 5000 iu/ml excipient: hydrochloric acid sodium hydroxide water for injection active: heparin sodium 5000 iu/ml excipient: benzyl alcohol hydrochloric acid sodium hydroxide water for injection

Jaunzēlande - angļu - Medsafe (Medicines Safety Authority)

baxter healthcare ltd - heparin sodium 2 iu/ml - solution for infusion - 2 u/ml - active: heparin sodium 2 iu/ml excipient: citric acid monohydrate dibasic sodium phosphate dodecahydrate sodium chloride water for injection - heparin sodium intravenous infusion is indicated as an anticoagulant in extracorporeal circulation, dialysis procedures, and as an aid in the maintenance of catheter patency.

Jaunzēlande - angļu - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - heparin sodium 5000 iu/ml;   - solution for injection - 25000 iu/5ml - active: heparin sodium 5000 iu/ml   excipient: hydrochloric acid sodium hydroxide water for injection